Olorunseun O. Ogunwobi, Chidiebere U. Awah (Hunter College)
Kevin Struhl (Harvard Medical School).
This invention enables the control of any transcript of interest. Specifically, herein, we
used the engineered destabilized ARE 3’ UTR of ERBB2 and MYC and reliably degraded
the ERBB2 and MYC expression in breast cancer cell lines BT474, MDA MB231, BT474
trastuzumab resistant cell line (BT474 R clone 5 ATCC) and in Osteosarcoma U20S and
SaOS2 and HOS cell lines.
Application Serial No. : 63/315,368 filed 20220301.
For more information or to license this innovation:
- Log In
to view the innovation's details
- Sign Up
with discount code "ECOS"
